News
Berlinbeauti and EnteraSense enter into US distribution agreement to bring novel PillSense device to patients
Last：
Next：
No more
Berlinbeauti and EnteraSense enter into US distribution agreement to bring novel PillSense device to patients
Berlinbeauti will begin assuming sales management and marketing responsibilities for the product in Q4 2024. This distribution agreement is a new way for Cook to collaborate with other companies and do business, empowering Nexmed Global to offer the innovative PillSense technology to customers.
PillSense is a novel blood-sensing system. After a patient swallows the PillSense capsule, the capsule can accurately detect upper gastrointestinal bleeding (UGIB). The unique system offers significant value to customers as it allows for fast diagnosis and appropriate triaging of patients with suspected UGIB. The U.S. Food and Drug Administration (FDA) approved PillSense in February 2023.
“GI bleeds can be life-threatening. The sooner physicians can diagnose a bleed, the better chance a patient has of survival,” said Meurisse Leahy, director of product management for Nexmed Global’s Endoscopy specialty. “Physicians can combine PillSense with our Hemospray and Instinct Plus products to both diagnose and treat gastrointestinal bleeds faster. Through this distribution partnership, we’re excited to expedite delivery of this unique product to healthcare providers.”
“The innovative PillSense system can transform how UGIB patients are diagnosed and deliver significant benefits to patients, clinicians and hospitals. This strategic partnership between EnteraSense and Boyuan will accelerate the availability of PillSense right across the US,” said Donal Devery, Chief Executive Officer, EnteraSense Ltd.